Clinical trials of β-blockers in heart failure: A class review

Clyde W. Yancy*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Heart failure remains a clinically challenging illness, with increasing incidence and prevalence and a high risk of mortality. The introduction of agents that interfere with the neurohormonal response to chronic left-ventricular dysfunction has resulted in improved patient outcomes. Owing to slowed disease progression and reduced mortality, angiotensin-converting enzyme (ACE) inhibitors are indicated in all patients with heart failure. New data indicate that in appropriate patients, β-blocker therapy relieves the symptoms associated with heart failure, reduces hospitalizations, and improves survival when added to standard therapy. Questions still remain regarding the ideal use of β blockers in heart failure, and ongoing trials will attempt to clarify those points.

Original languageEnglish (US)
Pages (from-to)7-10
Number of pages4
JournalAmerican Journal of Medicine
Volume110
Issue number5 SUPPL. 1
DOIs
StatePublished - Apr 2 2001

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Clinical trials of β-blockers in heart failure: A class review'. Together they form a unique fingerprint.

Cite this